caketin Funny what you pick up on when you go back and review things.
Just noticed on the RBS presentation at the bottom of slide 7 it refers to the report I found, so ACL are aware of it(as you think they well should be).
"
Fondaparinux commercialization
Partnered worldwide with Dr Reddy?s
Manufactured in India under license
Alchemia receives share of N. American operating profits
60% share of profit if only generic on market
Minimum profit share 50% if another generic launched
Alchemia to receive royalty on sales outside N. America
First generics typically gain market share rapidly after launch
30-60% market share*
Modest price discount to brand, generally ~20%*
*Source: Federal Trades Commission report on Authorized Generics, 2009"
http://www.alchemia.com.au/IRM/Company/ShowPage.aspx/PDFs/1702-16822205/PresentationtoRBSMorgans
http://www.ftc.gov/os/2009/06/P062105authorizedgenericsreport.pdf
- Forums
- ASX - By Stock
- TSN
- npat & valuation
npat & valuation, page-5
-
-
- There are more pages in this discussion • 74 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TSN (ASX) to my watchlist
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
TSN (ASX) Chart |
Day chart unavailable